JP6496731B2 - Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体 - Google Patents
Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体 Download PDFInfo
- Publication number
- JP6496731B2 JP6496731B2 JP2016534735A JP2016534735A JP6496731B2 JP 6496731 B2 JP6496731 B2 JP 6496731B2 JP 2016534735 A JP2016534735 A JP 2016534735A JP 2016534735 A JP2016534735 A JP 2016534735A JP 6496731 B2 JP6496731 B2 JP 6496731B2
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- pyrazol
- oxadiazol
- amine
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*C(*C(C)*)c1c(N)nc(*)c(-c2c[n](C3CCOCC3)nc2)c1* Chemical compound C*C(*C(C)*)c1c(N)nc(*)c(-c2c[n](C3CCOCC3)nc2)c1* 0.000 description 6
- MIASGWCNIHTJTB-UHFFFAOYSA-N CC#[N]1(C)=CC1 Chemical compound CC#[N]1(C)=CC1 MIASGWCNIHTJTB-UHFFFAOYSA-N 0.000 description 1
- LZKPVFMYGYHVGO-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1-c1nnc(-c2cc(Br)cnc2N)[o]1 Chemical compound CC(C)(C)c(cc1)ccc1-c1nnc(-c2cc(Br)cnc2N)[o]1 LZKPVFMYGYHVGO-UHFFFAOYSA-N 0.000 description 1
- JVBDBDHOLGYUIQ-UHFFFAOYSA-O CC(N(CC1)CCC1[NH2+]C=C(C=N)c(cc1-c2ncc(-c3cc(Cl)ccc3)[o]2)cnc1N)=O Chemical compound CC(N(CC1)CCC1[NH2+]C=C(C=N)c(cc1-c2ncc(-c3cc(Cl)ccc3)[o]2)cnc1N)=O JVBDBDHOLGYUIQ-UHFFFAOYSA-O 0.000 description 1
- SZQCPPRPWDXLMM-UHFFFAOYSA-N Cc1c[n](C)nc1 Chemical compound Cc1c[n](C)nc1 SZQCPPRPWDXLMM-UHFFFAOYSA-N 0.000 description 1
- ANVAZPCRAOPQIJ-UHFFFAOYSA-N Nc(c(-c1n[o]c(-c2ccccc2)n1)c1)ncc1-c1c[n](C2CCNCC2)nc1 Chemical compound Nc(c(-c1n[o]c(-c2ccccc2)n1)c1)ncc1-c1c[n](C2CCNCC2)nc1 ANVAZPCRAOPQIJ-UHFFFAOYSA-N 0.000 description 1
- PAEPKHUAPWJDPJ-UHFFFAOYSA-N Nc(c(-c1nnc(-c(c(Cl)ccc2)c2Cl)[o]1)c1)ncc1Br Chemical compound Nc(c(-c1nnc(-c(c(Cl)ccc2)c2Cl)[o]1)c1)ncc1Br PAEPKHUAPWJDPJ-UHFFFAOYSA-N 0.000 description 1
- NYNFTXIDIRRWRF-UHFFFAOYSA-N Nc(c(C(NCC(c1ccccc1)=O)=O)c1)ncc1Br Chemical compound Nc(c(C(NCC(c1ccccc1)=O)=O)c1)ncc1Br NYNFTXIDIRRWRF-UHFFFAOYSA-N 0.000 description 1
- YTWWWUDKKKOPHQ-UHFFFAOYSA-N Nc(c(C(NNC(c(c(Cl)ccc1)c1Cl)=O)=O)c1)ncc1Br Chemical compound Nc(c(C(NNC(c(c(Cl)ccc1)c1Cl)=O)=O)c1)ncc1Br YTWWWUDKKKOPHQ-UHFFFAOYSA-N 0.000 description 1
- FOTFDSYKXUMHPI-UHFFFAOYSA-N Nc(ncc(Br)c1)c1-c1nc(-c2ccccc2)n[o]1 Chemical compound Nc(ncc(Br)c1)c1-c1nc(-c2ccccc2)n[o]1 FOTFDSYKXUMHPI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361909828P | 2013-11-27 | 2013-11-27 | |
| US201361909830P | 2013-11-27 | 2013-11-27 | |
| US61/909,828 | 2013-11-27 | ||
| US61/909,830 | 2013-11-27 | ||
| PCT/US2014/067709 WO2015081257A2 (en) | 2013-11-27 | 2014-11-26 | Aminopyridine derivatives as tam family kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017501981A JP2017501981A (ja) | 2017-01-19 |
| JP2017501981A5 JP2017501981A5 (enExample) | 2017-11-16 |
| JP6496731B2 true JP6496731B2 (ja) | 2019-04-03 |
Family
ID=52146717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534735A Active JP6496731B2 (ja) | 2013-11-27 | 2014-11-26 | Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10233176B2 (enExample) |
| EP (1) | EP3074390B1 (enExample) |
| JP (1) | JP6496731B2 (enExample) |
| KR (1) | KR102398473B1 (enExample) |
| CN (2) | CN105764514B (enExample) |
| AU (1) | AU2014354711B2 (enExample) |
| BR (1) | BR112016012146B1 (enExample) |
| CA (1) | CA2930324C (enExample) |
| IL (1) | IL245660B (enExample) |
| MX (2) | MX373365B (enExample) |
| WO (1) | WO2015081257A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018224455A1 (en) | 2017-06-07 | 2018-12-13 | Basf Se | Substituted cyclopropyl derivatives |
| JP7366031B2 (ja) | 2017-09-22 | 2023-10-20 | カイメラ セラピューティクス， インコーポレイテッド | タンパク質分解剤およびそれらの使用 |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US20220356185A1 (en) * | 2018-07-06 | 2022-11-10 | Kymera Therapeutics, Inc. | Mertk degraders and uses thereof |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| MX2021003062A (es) | 2018-09-18 | 2021-05-27 | Signalchem Lifesciences Corp | Terapia combinada para tratar el cancer de sangre. |
| JP7623943B2 (ja) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2020251971A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4072591A4 (en) | 2019-12-10 | 2024-06-05 | Kymera Therapeutics, Inc. | IRAQ DEGRADER AND USES THEREOF |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| JP2023509366A (ja) | 2019-12-17 | 2023-03-08 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| CN115297931A (zh) | 2019-12-23 | 2022-11-04 | 凯麦拉医疗公司 | Smarca降解剂和其用途 |
| IL296451B2 (en) | 2020-03-19 | 2026-05-01 | Kymera Therapeutics Inc | MDM2 joints and their uses |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| EP4259144A4 (en) | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| CN112707898A (zh) * | 2020-12-21 | 2021-04-27 | 徐新杰 | 一种杂芳基取代的吡嗪衍生物及其应用 |
| WO2022147465A1 (en) | 2020-12-30 | 2022-07-07 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2022165436A1 (en) | 2021-02-01 | 2022-08-04 | Signalchem Lifesciences Corporation | Use of the axl inhibitor slc-391 as antiviral therapeutic agent |
| TW202245788A (zh) | 2021-02-15 | 2022-12-01 | 美商凱麥拉醫療公司 | Irak4降解劑及其用途 |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| EP4422635A4 (en) | 2021-10-29 | 2025-11-26 | Kymera Therapeutics Inc | IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS |
| WO2023086671A1 (en) * | 2021-11-15 | 2023-05-19 | The Broad Institute, Inc. | Compounds, compositions, and methods for inducing antimicrobial intracellular activity and for preventing and treating microbial infections |
| IL314437A (en) | 2022-01-31 | 2024-09-01 | Kymera Therapeutics Inc | IRAK joints and their uses |
| TW202545523A (zh) | 2024-02-05 | 2025-12-01 | 加拿大商聖諾康生命科學公司 | 用於治療血液癌症之組合療法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7884119B2 (en) | 2005-09-07 | 2011-02-08 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as Axl inhibitors |
| PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| WO2007111904A2 (en) * | 2006-03-22 | 2007-10-04 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors for the treatment of proliferative disorders |
| EP1900727A1 (en) * | 2006-08-30 | 2008-03-19 | Cellzome Ag | Aminopyridine derivatives as kinase inhibitors |
| WO2008045978A1 (en) | 2006-10-10 | 2008-04-17 | Rigel Pharmaceuticals, Inc. | Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors |
| US7879856B2 (en) | 2006-12-22 | 2011-02-01 | Rigel Pharmaceuticals, Inc. | Diaminothiazoles useful as Axl inhibitors |
| PT2078010E (pt) | 2006-12-29 | 2014-05-07 | Rigel Pharmaceuticals Inc | Triazoles substituídos com heteroarilos policíclicos úteis como inibidores de axl |
| JP2010514810A (ja) | 2006-12-29 | 2010-05-06 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ａｘｌインヒビターとして有用な置換トリアゾール |
| EP2114954B1 (en) | 2006-12-29 | 2013-02-13 | Rigel Pharmaceuticals, Inc. | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| AU2007342005A1 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors |
| ES2404668T3 (es) | 2006-12-29 | 2013-05-28 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con arilo bicíclico puenteado y heteroarilo bicíclico puenteado, útiles como agentes inhibidores del axl |
| CA2682733A1 (en) | 2007-04-13 | 2008-10-23 | Supergen, Inc. | Axl kinase inhibitors |
| PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| GB0713259D0 (en) | 2007-07-09 | 2007-08-15 | Astrazeneca Ab | Pyrazine derivatives 954 |
| WO2009024825A1 (en) | 2007-08-21 | 2009-02-26 | Astrazeneca Ab | 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JP2011500778A (ja) | 2007-10-25 | 2011-01-06 | アストラゼネカ・アクチエボラーグ | ピリジン及びピラジン誘導体−０８３ |
| CA2704052C (en) | 2007-10-26 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| EP2265270A1 (en) * | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
| EP2265574A1 (en) | 2008-02-29 | 2010-12-29 | Array Biopharma, Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| JP5746015B2 (ja) | 2008-04-16 | 2015-07-08 | マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー | Ａｘｌキナーゼ阻害剤としてのキノリン誘導体 |
| JP5592884B2 (ja) * | 2008-07-09 | 2014-09-17 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ａｘｌ阻害剤として有用な多環式ヘテロアリール置換トリアゾール |
| US8431594B2 (en) * | 2008-07-09 | 2013-04-30 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors |
| RU2555326C2 (ru) | 2009-01-16 | 2015-07-10 | Риджел Фармасьютикалз, Инк. | ИНГИБИТОРЫ Axl ДЛЯ ПРИМЕНЕНИЯ В КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ПРЕДОТВРАЩЕНИЯ, УСТРАНЕНИЯ ИЛИ ЛЕЧЕНИЯ МЕТАСТAЗИРУЮЩЕГО РАКА |
| JP2012517426A (ja) | 2009-02-09 | 2012-08-02 | アステックス ファーマシューティカルズ インコーポレイテッド | ピロロピリミジニルａｘｌキナーゼ阻害剤 |
| EP2311809A1 (en) | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
| ES2667049T3 (es) * | 2010-02-05 | 2018-05-09 | Merck Patent Gmbh | Derivados de heteroaril-[1,8]naftiridina |
| US8916593B2 (en) | 2010-05-04 | 2014-12-23 | Pfizer Inc. | Alkoxy-substituted 2-aminopyridines as ALK inhibitors |
| WO2011143422A1 (en) * | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | 2 -aminopyridine derivatives useful as inhibitors of atr kinase |
| EP2423208A1 (en) | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
| WO2012087938A1 (en) | 2010-12-20 | 2012-06-28 | Glaxosmithkline Llc | Quinazolinone derivatives as antiviral agents |
| EP3628665B1 (en) | 2011-04-01 | 2022-11-02 | University of Utah Research Foundation | Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase |
| UY34451A (es) | 2011-11-14 | 2013-05-31 | Cephalon Inc | Derivados de uracilo como inhibidores de la quinasa axl y c-met |
| MY165215A (en) | 2012-01-31 | 2018-03-09 | Daiichi Sankyo Co Ltd | Pyridone derivatives |
| WO2013162061A1 (ja) | 2012-04-26 | 2013-10-31 | 第一三共株式会社 | 二環性ピリミジン化合物 |
| WO2014106612A1 (en) * | 2013-01-02 | 2014-07-10 | H. Lundbeck A/S | Aminopyridine derived compounds as lrrk2 inhibitors |
-
2014
- 2014-11-26 CN CN201480065032.8A patent/CN105764514B/zh active Active
- 2014-11-26 KR KR1020167016444A patent/KR102398473B1/ko active Active
- 2014-11-26 MX MX2016006815A patent/MX373365B/es active IP Right Grant
- 2014-11-26 JP JP2016534735A patent/JP6496731B2/ja active Active
- 2014-11-26 CN CN201910548630.5A patent/CN110156770B/zh active Active
- 2014-11-26 BR BR112016012146-5A patent/BR112016012146B1/pt active IP Right Grant
- 2014-11-26 EP EP14819178.6A patent/EP3074390B1/en active Active
- 2014-11-26 CA CA2930324A patent/CA2930324C/en active Active
- 2014-11-26 AU AU2014354711A patent/AU2014354711B2/en active Active
- 2014-11-26 US US15/039,609 patent/US10233176B2/en active Active
- 2014-11-26 WO PCT/US2014/067709 patent/WO2015081257A2/en not_active Ceased
-
2016
- 2016-05-16 IL IL245660A patent/IL245660B/en active IP Right Grant
- 2016-05-25 MX MX2020005181A patent/MX2020005181A/es unknown
-
2019
- 2019-01-22 US US16/254,208 patent/US10723725B2/en active Active
-
2020
- 2020-06-11 US US16/899,494 patent/US11034686B2/en active Active
- 2020-06-11 US US16/899,489 patent/US11034685B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020005181A (es) | 2020-08-17 |
| US20190152965A1 (en) | 2019-05-23 |
| BR112016012146B1 (pt) | 2022-11-01 |
| MX2016006815A (es) | 2016-12-02 |
| IL245660B (en) | 2020-01-30 |
| US11034685B2 (en) | 2021-06-15 |
| WO2015081257A2 (en) | 2015-06-04 |
| BR112016012146A8 (pt) | 2018-01-30 |
| EP3074390A2 (en) | 2016-10-05 |
| US10723725B2 (en) | 2020-07-28 |
| WO2015081257A3 (en) | 2015-07-02 |
| KR102398473B1 (ko) | 2022-05-16 |
| AU2014354711A1 (en) | 2016-06-02 |
| CN105764514A (zh) | 2016-07-13 |
| CN110156770B (zh) | 2022-10-04 |
| AU2014354711B2 (en) | 2018-10-25 |
| KR20160091358A (ko) | 2016-08-02 |
| CA2930324A1 (en) | 2015-06-04 |
| EP3074390B1 (en) | 2020-07-08 |
| BR112016012146A2 (pt) | 2017-08-08 |
| US11034686B2 (en) | 2021-06-15 |
| US20200299288A1 (en) | 2020-09-24 |
| MX373365B (es) | 2020-05-26 |
| IL245660A0 (en) | 2016-06-30 |
| CA2930324C (en) | 2022-01-18 |
| CN110156770A (zh) | 2019-08-23 |
| US10233176B2 (en) | 2019-03-19 |
| CN105764514B (zh) | 2019-07-12 |
| US20170022189A1 (en) | 2017-01-26 |
| JP2017501981A (ja) | 2017-01-19 |
| US20200299287A1 (en) | 2020-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11034685B2 (en) | Aminopyridine derivatives as TAM family kinase inhibitors | |
| JP4173738B2 (ja) | Ｅｒｋ２の複素環式インヒビターおよびその使用 | |
| CA3140257C (en) | Next-generation modulators of stimulator of interferon genes (sting) | |
| JPWO2007007910A1 (ja) | ヘテロ環置換ベンズイミダゾール誘導体 | |
| TW202045498A (zh) | 作為法尼醇x受體調節劑之經取代雙環化合物 | |
| CN115697991A (zh) | 哌嗪环状脲 | |
| CN105916506B (zh) | 作为tam家族激酶抑制剂的喹唑啉衍生物 | |
| CN115697972A (zh) | 包括哌嗪杂环酰胺脲的受体-相互作用蛋白1抑制剂 | |
| EP4463452B1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| JP2023505703A (ja) | Ｌｐａ受容体２阻害剤としての芳香族アミド誘導体 | |
| JP7618898B1 (ja) | ヒト呼吸器合胞体ウイルス及びメタニューモウイルスの阻害薬 | |
| HK1228911B (en) | Aminopyridine derivatives as tam family kinase inhibitors | |
| HK1228911A1 (en) | Aminopyridine derivatives as tam family kinase inhibitors | |
| TW202409011A (zh) | 人類呼吸道融合病毒及間質肺病毒抑制劑 | |
| HK40087839A (zh) | 哌嗪环状脲 | |
| HK1228287B (zh) | 作为tam家族激酶抑制剂的喹唑啉衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171004 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171004 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180614 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180703 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181002 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181129 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190305 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190311 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6496731 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |